|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Alterations in <i>MEK1/2</i> occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in <i>BRAF</i>-V600E-mutant melanoma and colorectal cancer.
|
28655712 |
2017 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer.
|
25176643 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after CRC diagnosis among subgroups of patients.
|
22899730 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
|
26438153 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome.
|
26160848 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CRCs) harboring hMLH1 methylation but not Lynch syndrome-related CRCs.
|
17942460 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We evaluated miR-31-5p expression and gene mutations [KRAS (codon 61 or 146), NRAS (codon 12, 13, or 61), and BRAF (V600E)] in the EGFR downstream pathway in 102 CRC patients harboring KRAS (codon 12 or 13) wild-type who were treated with anti-EGFR therapeutics.
|
25472647 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We used preclinical models of CRC to demonstrate (18)F-FLT PET as a sensitive predictor of response to (V600E)BRAF inhibitors.
|
23341544 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Multitarget stool DNA testing for colorectal-cancer screening.
|
25006736 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We analyzed sporadic CRCs in Omani (of African origin, N = 61), Iranian (of Caucasian origin, N = 53) and African American (N = 95) patients for microsatellite instability, expression status of mismatched repair genes (hMLH1, hMSH2) and presence of the BRAF (V600E) mutation.
|
18718023 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Sporadic MSI CRC often harbours BRAF(V600E); however, no consistent data exist regarding targeted treatment approaches in BRAF(wt) MSI CRC.
|
26001389 |
2016 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
|
24996433 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
MLH1 promoter methylation and V600E BRAF mutation analysis were investigated on 61 CRCs.
|
31609810 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
|
22138009 |
2011 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Our data show that IHC could be used in routine clinical practice as a screening method for BRAF V600E mutant protein detection in CRC patients.
|
27569082 |
2016 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We provide a global assessment of gene expression motifs that differentiate BRAF V600E subtypes from other colorectal cancers.
|
27354468 |
2017 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.
|
18628431 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The aim of this study was to relate the CpG island methylator phenotype (CIMP; characterized by extensive promoter hypermethylation) to cancer-specific survival in colorectal cancer, taking into consideration relevant clinicopathologic factors, such as microsatellite instability (MSI) screening status and the BRAF V600E mutation.
|
20197478 |
2010 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The association of BRAF V600E mutation and the presence of the CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) often confound analysis of BRAF mutation status and survival in colorectal carcinoma.
|
22314188 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304.
|
29755114 |
2018 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorectal cancer, its determination provides a diagnostic exclusion criterion for hereditary nonpolyposis colorectal cancer.
|
19213871 |
2009 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We screened 535 formalin-fixed paraffin-embedded CRC tissue samples for the BRAF V600E mutation, and selected 7 BRAF-mutated and 7 KRAS-mutated CRCs that were tumor size, stage, and microsatellite status-matched.
|
27082577 |
2016 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer patients with BRAF V600E mutation.
|
24248543 |
2014 |